NeurologyLive

5 days ago | neurologylive.com | Marco Meglio

Using more than 250,000 person years (PYs) of exposure data, results from a recent analysis showed that the safety profile of cladribine (Mavenclad; EMD Serono), an FDA-approved medication for multiple sclerosis (MS), was consistent with findings from its clinical development program and previous safety updates.

5 days ago | neurologylive.com | Marco Meglio

Newly reported data from the phase 3 OPTIMUM-LT open-label extension trial (NCT03232073) showed that treatment with ponesimod (Ponvory; Vanda Pharmaceuticals) was safe and led to sustained reduction in relapses, MRI lesions, and low disability accumulation among patients with relapsing multiple sclerosis over a long-term period.

5 days ago | neurologylive.com | Marco Meglio

In a survey of Members of the Medical Partnership 4 MS+ (MP4MS+), a group of more than 1300 neurologists, a large majority of respondents agreed that disability, age, and ambulation should not preclude disease-modifying therapy (DMT) use in older patients with multiple sclerosis (MS). Overall, most neurologist felt that individualized assessment, rather than age-based rules, should be applied when considering DMT discontinuation following long-term stability.

5 days ago | neurologylive.com | Marco Meglio

Newly presented results from the open-label extension (OLE) of the phase 2 FENopta study (NCT05119569) showed that patients with relapsing multiple sclerosis (RMS) on fenebrutinib (Genentech) had low relapse rates with no active brain lesions or disability progression after 2 years of treatment.

6 days ago | neurologylive.com | Marco Meglio

Findings from a non-interventional primary data collection study of adults with multiple sclerosis (MS) showed that significantly higher patients on ocrelizumab (Ocrevus; Genentech) experienced wearing off related symptom worsening while on medication than those prescribed ofatumumab (Kesimpta; Novartis).1The real-world study comprised 75 patients treated with ofatumumab for at least 6 months and 60 on ocrelizumab for at least 1 year.